Related references
Note: Only part of the references are listed.Does 1-(R)-aminoindan Possess Neuroprotective Properties Against Experimental Parkinson's Disease?
Orly Weinreb et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
Challenges to the development of disease-modifying therapies in Parkinson's disease
A. H. V. Schapira
EUROPEAN JOURNAL OF NEUROLOGY (2011)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
Olivier Rascol et al.
LANCET NEUROLOGY (2011)
Parkinson disease clinical subtypes and their implications
Anthony H. V. Schapira et al.
NATURE REVIEWS NEUROLOGY (2011)
Safinamide in the treatment of Parkinson's disease
Anthony H. V. Schapira
EXPERT OPINION ON PHARMACOTHERAPY (2010)
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
Orit Bar-Am et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Movement disorders: advances in cause and treatment
Anthony H. V. Schapira
LANCET NEUROLOGY (2010)
Molecular and clinical prodrome of Parkinson disease: implications for treatment
Anthony H. V. Schapira et al.
NATURE REVIEWS NEUROLOGY (2010)
Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells
K. Y. Chau et al.
NEUROCHEMISTRY INTERNATIONAL (2010)
Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis
H. Nissinen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Levodopa in the treatment of Parkinson's disease
A. H. V. Schapira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Perspectives on recent advances in the understanding and treatment of Parkinson's disease
A. H. Schapira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2009)
Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease
Anthony H. V. Schapira
NEUROLOGY (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Neurobiology and treatment of Parkinson's disease
Anthony H. V. Schapira
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Why Have We Failed to Achieve Neuroprotection in Parkinson's Disease?
C. Warren Olanow et al.
ANNALS OF NEUROLOGY (2008)
Drug Selection and Timing of Initiation of Treatment in Early Parkinson's Disease
Anthony H. V. Schapira et al.
ANNALS OF NEUROLOGY (2008)
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration
Wen Zhu et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs
Claudia Binda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Treatment options in the modern management of Parkinson Disease
Anthony H. V. Schapira
ARCHIVES OF NEUROLOGY (2007)
Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism
Yotam Sagi et al.
NEUROBIOLOGY OF DISEASE (2007)
TCH346 as a neuroprotective drug in Parkinsons disease: a double-blind, randomised, controlled trial
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Symptom relief in Parkinson disease by safinamide - Biochemical and clinical evidence of efficacy beyond MAO-B inhibition
F. Stocchi et al.
NEUROLOGY (2006)
Novel pharmacological targets for the treatment of Parkinson's disease
Anthony H. V. Schapira et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Selegiline slows the progression of the symptoms of Parkinson disease
S Pålhagen et al.
NEUROLOGY (2006)
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
AHV Schapira et al.
ANNALS OF NEUROLOGY (2006)
Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease
JJ Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives
S Mandel et al.
BRAIN RESEARCH REVIEWS (2005)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O Rascol et al.
LANCET (2005)
Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells
D Bonneh-Barkay et al.
NEUROPHARMACOLOGY (2005)
Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
MBH Youdim et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
O Bar Am et al.
NEUROSCIENCE LETTERS (2004)
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
NJ Ives et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Improvement of motor function in early Parkinson disease by safinamide
F Stocchi et al.
NEUROLOGY (2004)
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity
A Marzo et al.
PHARMACOLOGICAL RESEARCH (2004)
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
F Blandini et al.
EXPERIMENTAL NEUROLOGY (2004)
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease
P Jenner
NEUROLOGY (2004)
Clinical trials of neuroprotection for Parkinson's disease
PA LeWitt
NEUROLOGY (2004)
N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor
W Maruyama et al.
NEUROCHEMISTRY INTERNATIONAL (2004)
Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor
W Maruyama et al.
NEUROSCIENCE LETTERS (2003)
The relevance of preclinical studies for the treatment of Parkinson's disease
M Gerlach et al.
JOURNAL OF NEUROLOGY (2003)
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
I Shoulson et al.
ANNALS OF NEUROLOGY (2002)
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-3R)aminoindan-5-YL)-ethyl methyl carbamate
MBH Youdim et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2001)
Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol
W Maruyama et al.
JOURNAL OF NEUROCHEMISTRY (2001)
L-deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP+ and β-carbolinium:: a microdialysis study in rats
K Matsubara et al.
NEUROSCIENCE LETTERS (2001)
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline
A Kupsch et al.
JOURNAL OF NEURAL TRANSMISSION (2001)
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
MBH Youdim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Share Paper
